ONCO BRUNO

#ALK is a viable target even in squamous NSCLC, demonstrated by this case + review in @ClinicalLung. However, significant variability in quality of response. While most respond, many brief courses of crizotinib, one on 1L alectinib for 5y and counting. clinical-lung-cancer.com/article/S1525-…

#FLAURA2 Catching up with the press release medical literature. Chemo+osimertinib for 1L EGFR+ NSLC now has OS advantage over osi monotherapy. ➡️Magnitude of OS benefit not reported yet , PFS 29.4 vs 19.9mo (HR 0.75) ➡️ Who gets chemo+tki vs amivantamab+TKI is the ?? ➡️ Weigh…

We were asked to amplify @lungoncdoc ‘s polling questions- so here u go #lcsm PLS ANSWER HIS QUESTIONS!!! @NarjustFlorezMD

Polling Q4. EGFRm NSCLC Beyond 1L‼️ Should EGFR inhibition be continued beyond progression? #BTGLung2025 @NarjustFlorezMD @DrEdKim @BalazsHalmosMD @LeXiuning @OncLive

‼️Polling Q2. Emerging treatment options in SCLC What do you see as the most promising strategy to improve OS in SCLC? #BTGLung2025 @sands_jacob @triparnasen @NarjustFlorezMD @DrEdKim @AnaVManana @OncLive

Hi 👋 all practicing oncologists connections. We can give you access for free to our CLIN onco data platform ($3k a year value). Just drop a comment.

Treatment outcome of NSCLC patients with BRAFnon-V600Emutations: a retrospective, multicentre analysis within the nNGM Lung Cancer in Germany in @ESMO_Open. Different results with targeted therapies by mutation type even among non-V600E NSCLC. esmoopen.com/article/S2059-…

Somewhat expected given STARGLO ODAC vote in May. Hopefully not a sign of things to come for Blenrep. #mmsm #lymsm Lack of US Data Stymie Roche’s Earlier-Stage Lymphoma Push for Columvi biospace.com/fda/lack-of-us…

We successfully completed both P8 and P9 this weekend, our first time performing two surgeries in one day. Both participants are recovering well and in great spirits. We are looking forward to supporting them on their Neuralink journey.

ADCs are a next frontier. Our work with the Larvol group on nectin4 pubmed.ncbi.nlm.nih.gov/40209851/

This is an exciting development in the treatment of EGFR-mutated advanced lung cancer. The combination of Tagrisso and chemotherapy showing significant improvement in overall survival is a promising step forward. Did the trial address any potential resistance mechanisms that…

🧠💊 AI is transforming cancer care: 🔍 Early detection 🧬 Precision treatment 💉 Smarter immunotherapy 💊 Faster drug discovery 📈 Predicting relapse LARVOL AI is doing exactly this to fight the deadliest cancers. #AI #Onco @Larvol @brunolarvol 🔬 Stay tuned for new updates.

#KEYNOTE689: Adding #Pembrolizumab before and after surgery significantly improves EFS in resectable LA-HNSCC. A potential new standard of care after 20+ years of stagnation. bit.ly/4cVzF0j #LARVOL #AACR25 #HNSCC #CancerResearch @DrUppaluri

Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer. Learn more about FLAURA2 👉 clin.larvol.com/trial-detail/N… #LARVOL #CancerResearch #Oncology #ClinicalTrials #CancerData…

🧠 FLAURA2: CNS activity with osimertinib + chemo vs osimertinib alone. @dplanchard 💊 Now you have a subgroup of patients with EGFR mutation who can benefit from treatment intensification upfront. #ESMO23 #LCSM @EGFRResisters

Very elegant slide from FLAURA2 by @dplanchard. It highlights, for the osimertinib+chemo arm: - transient toxicities of chemo - potential tachyphylaxia for osi (some symptoms improve spontaneously) - low grade long lasting toxicities that are rarely properly reported. #ESMO23

FDA Advisory Committee Rejects Blenrep Combo Therapies—But a Positive Vote is Possible for Myeloma Patients Seeking New Options healthtree.org//myeloma/commu….

FLAURA2- Baseline detection of ctDNA may identify a subgroup of pts who derive most benefit from addition of chemoT to osimertinib as first line trtt for EGFRmut NSCLC by P.Jänne at #AACR24 @EGFRResisters @DFEGFRcenter @GustaveRoussy @DanaFarberNews